DNA repair dysfunction in cancer induced by altered BRCA2 localization
DNA repair dysfunction in cancer induced by altered BRCA2 localization
批准号:
10739521
负责人:
Judit Jimenez Sainz
金额:
$20.58万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-12 至 2026-08-31
关键词:
AffectAntibodiesAwardBiochemistryBiologicalBiologyBreast Cancer DetectionBreast Cancer geneC-terminalCancer BiologyCancer DiagnosticsCancer EtiologyCancer PatientCancer-Predisposing GeneCell NucleusCell modelCellular biologyCentrosomeChromosome MappingClinical ManagementCytoplasmCytosolDNADNA Binding DomainDNA DamageDNA Double Strand BreakDNA RepairDNA Repair GeneDNA Repair PathwayDNA replication forkDefectDevelopmentDouble Strand Break RepairEnsureFamily memberFrameshift MutationFunctional disorderGene ExpressionGene MutationGenome StabilityGenomic InstabilityGoalsHereditary Breast and Ovarian Cancer SyndromeHumanInstitutionKnowledgeLeadMalignant NeoplasmsMass Spectrum AnalysisMeasuresMissense MutationMolecularMutationNonsense MutationNormal CellNuclearNuclear ImportNuclear Localization SignalNuclear ProteinOncogenesPancreasPathogenicityPathway interactionsPatientsPharmaceutical PreparationsPlatinumPoly(ADP-ribose) Polymerase InhibitorPositioning AttributePostdoctoral FellowPreventionPrincipal InvestigatorProcessProteinsProteomicsReportingResearchRisk AssessmentTestingTherapeutic InterventionTimeTissue MicroarrayTissue SampleTreatment outcomeTumor TissueUncertaintyVariantcancer cellcancer geneticscancer riskcarcinogenesiscareerclinical applicationdiagnostic tooldriver mutationgenetic testinggenetic variantgenome integrityhereditary riskhuman tissuemalignant breast neoplasmmelanomaneoplastic cellnovelnucleocytoplasmic transportpatient stratificationpreventprostate cancer riskprotein foldingprotein misfoldingreconstitutionrepair functionrepairedresponserisk stratificationskill acquisitionsuccesstargeted cancer therapytargeted treatmenttherapy resistanttooltraffickingtumorvariant of unknown significancevirulence gene
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
BRCA2, as part of the DNA repair pathway, is a key regulator in homology-directed repair (HDR) and fork protection
mechanism, which ensures genome instability. For full activity, BRCA2 must be transported into the nucleus to repair
DNA double-strand breaks (DSBs). In normal cells, loss of nuclear BRCA2 can lead to genome instability and cancer
but, in tumor cells, BRCA2 cytosolic mislocalization can lead to sensitivity to targeted therapies.
I identified a paradoxical relationship between BRCA2 nuclear import and treatment. Pathogenic missense mutations
in the DNA binding domain of BRCA2 direct the protein to the cytosol which increase sensitivity to PARP inhibitors
(PARPi) and platinum drugs. Therefore, although BRCA2 mislocalization might be a cause of cancer, keeping it
out of the nucleus allows for much better treatment outcomes. This has opened an avenue of research that I am
perfectly aligned to study. In this K22 proposal I will address the nuclear transport of BRCA2, how cancer-driver
mutations lead to cytosolic mislocalization and how BRCA2 localization can be used as a diagnostic tool. To test this, I
will define the molecular mechanism(s) regulating nuclear/cytoplasmic shuttling of BRCA2 pathogenic missense
variants (Aim 1), determine the impact of BRCA2 cellular localization on HDR, fork protection and cytosolic processes
(Aim 2) and exploit BRCA2 localization as a cancer diagnostic tool (Aim 3). My priority will be to focus on missense
variants identified during my postdoctoral career to decipher the underlying molecular mechanism of nuclear/cytosolic
BRCA2 trafficking. At the successful completion of this K22 proposal, I will reveal novel pathways and factors that ensure
proper localization of BRCA2 and how pathogenic BRCA2 missense variants have altered localization and functionality.
This knowledge will give us a better understanding of the pathogenicity of BRCA2 missense variants and how we can
modulate the functionality of BRCA2.
My career goal is to obtain an independent position at a leading institution where I will dissect the functionality of
missense variants in DNA repair proteins and how their cellular localization is important for genome stability as a tool to
predict cancer risk and to treat cancer patients. My successful transition will be supported by advancing my expertise in
cell biology, biochemistry, mass spectrometry and human cellular models. I will use these acquired skills to define why
and how certain pathogenic BRCA2 missense variants are mislocalized to the cytosol. Importantly, the protected time
that this award provides me will allow me to elucidate the factors and pathways by which BRCA2 is transported from
the cytosol to the nucleus, how this might be altered in BRCA2 missense variants and how this could be used for
targeted therapies. Furthermore, the success of this project will be greatly enhanced by the outstanding advisors and
collaborators that advise me through the K22 period. The receipt of this award will allow me to expand my research plan
and establish myself as a principal investigator in the field of cancer biology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金